| Abstrakt: |
A recent study conducted at the University Clinic of Respiratory and Allergic Diseases Golnik in Slovenia explored the use of an autoimmune mast cell activation test (aiMAT) as a diagnostic tool for chronic spontaneous urticaria (CSU). The researchers enrolled 43 CSU patients and 15 controls and evaluated their response to omalizumab therapy. The study found that the aiMAT showed promise as a diagnostic tool for CSU, with a sensitivity of 73.3% and specificity of 81.4%. However, further research is needed to fully understand the benefits of aiMAT during omalizumab therapy. [Extracted from the article] |
